Pharmaceutical Biotech sold the Irish vaccine facility to MSD for 500 million US dollars, close to its total construction cost of 480 million US dollars. The company pointed out that return on investment was the main consideration behind this transaction. Morgan Stanley published a report saying that since the asset's return on investment for Yao Ming Biotech is below target, the deal appears to be a win-win situation for both parties, according to Pharmaceutical Kangde's management. However, the operation of the company's other Irish facilities remained unchanged, with a gross margin of about 40% during the stable phase. Regarding the use of cash proceeds, Yao Ming Kangde will further repurchase shares and make higher-return investments. Due to the good return on investment, there are currently no other assets to sell. According to Daimo, although the sale of assets will cost Yao Ming Biotech's short-term revenue, it believes that this transaction will have a positive impact on the company's profitability, return on investment, and cash usage efficiency. Therefore, it reaffirms Pharmaceutical's “increase” rating, with a target price of HK$31.6.

Pharmaceutical Biotech sold the Irish vaccine facility to MSD for 500 million US dollars, close to its total construction cost of 480 million US dollars. The company pointed out that return on investment was the main consideration behind this transaction. Morgan Stanley published a report saying that since the asset's return on investment for Yao Ming Biotech is below target, the deal appears to be a win-win situation for both parties, according to Pharmaceutical Kangde's management. However, the operation of the company's other Irish facilities remained unchanged, with a gross margin of about 40% during the stable phase. Regarding the use of cash proceeds, Yao Ming Kangde will further repurchase shares and make higher-return investments. Due to the good return on investment, there are currently no other assets to sell. According to Daimo, although the sale of assets will cost Yao Ming Biotech's short-term revenue, it believes that this transaction will have a positive impact on the company's profitability, return on investment, and cash usage efficiency. Therefore, it reaffirms Pharmaceutical's “increase” rating, with a target price of HK$31.6.